Occupancy Versus Agonist And Antagonist Efficacy

Why Occupancy Does Not Specify Activity

A ligand can bind many receptors without activating them. Conversely, two ligands can occupy the same fraction of a receptor population yet produce different degrees of receptor activation. This distinction matters when interpreting target engagement: a binding measurement describes how much target is occupied, not what the occupied target does.

The key comparison in this tutorial is between occupancy, the fraction of receptors bound by ligand, and efficacy, the capacity of a ligand-bound receptor to support activity. A neutral antagonist can have substantial occupancy while contributing no activating activity in the receptor-state model below. A partial agonist can occupy the same fraction as a full agonist but contribute less activity per occupied receptor.

Occupancy depends on binding conditions, including free ligand concentration and affinity. Efficacy is a separate property of the ligand-receptor interaction. Neither property, by itself, is a complete prediction of a measured downstream response. Here, “activity” refers only to a simplified, normalized receptor-level stimulus; it is not a concentration-response model for a cellular or clinical endpoint.

A Receptor-State Model for Comparing Efficacy

Suppose a homogeneous receptor population has one mutually exclusive binding site per receptor. Let \(\theta_i\) be the fraction of all receptors occupied by ligand \(i\), and let \(\theta_0\) be the unoccupied fraction. The fractions satisfy \(\theta_0+\sum_i\theta_i=1\). Assign the unoccupied state zero activity relative to basal activity, and assign each occupied state a relative efficacy \(\epsilon_i\). Choose a reference full agonist to have \(\epsilon=1\); a partial agonist has \(0<\epsilon_i<1\), and a neutral antagonist has \(\epsilon_i=0\).

In this deliberately simple model, \(S\) is the mean normalized receptor-level stimulus across the population. If only one ligand is present, its contribution is \(S=\epsilon\theta\). Thus equal occupancy gives equal stimulus only when the ligands also have equal efficacy. The calculation does not establish that a downstream measured response is proportional to \(S\).

For equilibrium competition at a shared site, define \(x_i=[L_i]/K_{D,i}\), where \([L_i]\) is the free concentration of ligand \(i\) and \(K_{D,i}\) is its equilibrium dissociation constant. Under the one-site equilibrium assumptions, the occupancy by ligand \(i\) and the total occupancy are

These expressions determine how receptors are distributed among the unbound and ligand-bound states. The efficacy-weighted sum then distinguishes the activity associated with those states. A binding assay that reports only total occupancy does not, on its own, reveal how much of that occupancy belongs to an agonist versus an antagonist.

Why the Weighted-Sum Calculation Works

The expression for \(S\) follows from averaging the activity of receptor states. Imagine a large population of \(N\) receptors. Approximately \(N\theta_i\) receptors are in state \(i\), and each contributes \(\epsilon_i\) normalized activity units. The unbound receptors contribute zero under the model’s chosen baseline. The total activity is therefore \(\sum_i (N\theta_i)\epsilon_i\). Dividing by \(N\), the number of receptors, gives the mean activity per receptor:

This is an averaging identity, not a general law that cellular output must be linear in occupancy. If receptor states interact or if signaling amplifies or saturates downstream, the measured response can depart from this simple average. Keeping the interpretation at the receptor-state level prevents the calculation from being mistaken for a full pharmacodynamic model.

Interpreting Efficacy and Diagnosing Misleading Comparisons

A partial agonist is not simply a weakly binding agonist. Binding affinity and efficacy answer different questions: affinity concerns binding, while efficacy concerns activity conditional on binding. A ligand can bind tightly yet have low efficacy, or bind less tightly yet have high efficacy. Comparing two ligands at the same concentration does not generally hold occupancy constant; if occupancy differs, a difference in calculated stimulus may reflect both occupancy and efficacy.

To isolate efficacy in the simple model, compare ligands at matched occupancy, or explicitly calculate each ligand’s occupied fraction and then apply its efficacy. In practical data, first check whether the occupancy values refer to fractions of the same receptor population and whether the ligands compete for the same site. Also check whether “occupancy” means total occupied receptors or ligand-specific occupancy. Those quantities are not interchangeable when more than one ligand is present.

The numerical efficacy scale is a comparison convention in this tutorial: the reference full agonist is set to \(1\). In empirical pharmacology, efficacy can be system-dependent and may be estimated indirectly from functional experiments; it is not necessarily a universal constant that can be read directly from a binding assay. The introductory material on receptor states and fractional occupancy establishes the state-fraction interpretation; the present comparison adds the distinction between how many receptors are bound and the activity assigned to each bound state.

Common Pitfalls and Limits

• Equating occupancy with activation. The mistaken reasoning is that \(80\%\) occupancy must mean \(80\%\) activation. Occupancy alone does not specify efficacy; a neutral antagonist at \(80\%\) occupancy contributes zero activating stimulus in this model.
• Calling a partial agonist a low-affinity ligand. Partial agonism concerns lower activity per occupied receptor relative to a reference agonist, not necessarily weaker binding.
• Using total occupancy as if it identified the bound ligand. The same total occupancy can have different efficacy-weighted activity if the ligand mixture differs. Use ligand-specific fractions when evaluating the model.
• Treating \(S\) as a measured response. The weighted sum is a simplified receptor-level quantity. Without an explicit model connecting receptor states to the measured endpoint, it should not be reported as a predicted cellular or clinical effect.
• Assuming efficacy is independent of experimental context. The reference ligand, receptor subtype, and assay system must be specified when interpreting efficacy comparisons; changing the context can change the observed functional ranking or scale.

The model is useful for separating two concepts and checking whether an occupancy-based interpretation is plausible. It is limited when receptor populations are heterogeneous, binding is cooperative, receptor states interact, or the relevant biological output depends on nonlinear processes. In those settings, the simple weighted average is an organizing comparison, not a substitute for a model suited to the measured system.